论文部分内容阅读
分别对２５例卵巢恶性上皮性肿瘤患者化疗期间以及８例存活时间≥５年的患者二次探查术前、后的血清ＣＡ１２５值进行了动态监测。结果：术前或首次化疗期间，血清ＣＡ１２５值≥６５Ｕ／ｍｌ者占８０％（２０／２５）。在化疗第３疗程之前，６３３％（１４／２２）患者血清ＣＡ１２５值降至≤３５Ｕ／ｍｌ；６例血清ＣＡ１２５值≥６５Ｕ／ｍｌ患者中，５例盆腔内有癌肿持续存在。化疗第３疗程以后各疗程期间，血清ＣＡ１２５值≥３５Ｕ／ｍｌ者６例，５例盆腔内有癌肿的复发或持续存在。存活时间≥５年、二次探查术组织病理学检查结果阴性的５例中，４例血清ＣＡ１２５值持续＜２０Ｕ／ｍｌ；癌肿复发者３例，其血清ＣＡ１２５值均＞６５Ｕ／ｍｌ。化疗期间，８例癌肿复发者中，有６例血清ＣＡ１２５值升高，较临床发现早４个月。说明血清ＣＡ１２５值是监测卵巢恶性上皮性肿瘤临床病程变化的敏感肿瘤标记物；化疗第３疗程之前，动态监测血清ＣＡ１２５值下降幅度是评价化疗效果及预后重要而有效的手段。
Twenty-five patients with malignant epithelial ovarian tumors and eight patients with a survival time of ≥5 years were monitored dynamically for CA125 before and after the second exploration. RESULTS: Preoperatively or during the first chemotherapy period, serum CA125 values ≥ 65 U/ml accounted for 80% (20/25). Before the third course of chemotherapy, the serum CA125 value of 63. 3% (14/22) patients dropped to ≤ 35 U/ml; of the 6 patients with serum CA125 values ≥ 65 U/ml, 5 cases had persistent pelvic cancer. During the course of treatment after the third course of chemotherapy, serum CA125 values were higher than 35 U/ml in 6 cases, and 5 cases had recurrence or persistent cancer in the pelvis. Among the 5 patients whose survival time was ≥5 years and whose histological examination results were negative after the second exploratory operation, serum CA125 values were <20 U/ml in 4 cases, and CA125 values were >65 U/ml in 3 cases of cancer recurrence. During chemotherapy, serum CA125 levels were elevated in 6 of 8 cases of cancer recurrence, which was 4 months earlier than the clinical findings. It is concluded that serum CA125 value is a sensitive tumor marker to monitor the clinical course of malignant epithelial ovarian tumors; before the third course of chemotherapy, the dynamic monitoring of the decrease of serum CA125 value is an important and effective means to evaluate the effect of chemotherapy and prognosis.